openPR Logo
Press release

Biosimilar Market to Cross US$ 11 Billion by 2021

06-15-2017 01:53 PM CET | Health & Medicine

Press release from: (MRE) Reports

Biosimilar Market

Biosimilar Market

New York, June 15: Market Research Engine has published a new report titled as “Biosimilar Market By Manufacturing Type Analysis (In-house Manufacturing, Contract Manufacturing Organizations); By Application Analysis (Oncology, Blood Disorders, Chronic & Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases); By Product Analysis (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides) and By Regional Analysis – Global Forecast by 2016 - 2022”

How Big is the Global Biosimilar Market?

The Biosimilar Market is expected to exceed more than US$ 10.90 Billion by 2021 at a CAGR of 26.3% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/biosimilar-market-report

A biosimilar is a biologic remedial item which is right around an indistinguishable duplex of a unique item that is made by an alternate company. Biosimilars are formally affirmed variants of unique "trailblazer" items, and can be fabricated when the first item's patent lapses or gets due. Biosimilars are created in living cells with a multi-step procedure. They should be taken care of and controlled under precisely checked conditions. Biosimilars are utilized to forestall, treat, analyze, or cure an assortment of genuine and ceaseless sicknesses including malignancy, unending kidney illness, immune system issue, and irresistible maladies. The biosimilar market is fragmented on the premise of item, assembling sort, and application. Research and development in biosimilar markets and new signs and patent expiry of biologic items has opened globally a new gate of chances for players in the biosimilar market.

The major driving factors of Biosimilar Market are as follows:

• Expanding Government Support and Initiatives to Develop and Promote Biosimilars
• Developing Pressure to Curtail Healthcare Expenditure
• Growth in population of senior citizens
• Increasing Pressure to reduce or cut Healthcare Expenditure
• Increase in clinical trial activities and awareness
• Low cost of biosimilar drugs increases the demand for use

The restraining factors of Biosimilar Market are as follows:

• Complexities in assembling and creative procedures by biologic medication producers.

The Biosimilar Market is segmented on the lines of its product, application, manufacturing type and regional. Based on product segmentation it covers recombinant non-glycosylated proteins, recombinant glycosylated proteins, recombinant peptides. Based on application segmentation it covers oncology, blood disorders, chronic & autoimmune diseases, growth hormone deficiency, infectious diseases, other applications. Based on manufactured type it covers in-house manufacturing, contract manufacturing organizations. The Biosimilar Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

This report provides:

1) An overview of the global market for Biosimilar Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
3) Identifications of new market opportunities and targeted promotional plans for Biosimilar Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets onBiosimilar Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion, Inc. (South Korea), and Biocon Ltd. (India). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.

The Biosimilar Market has been segmented as below: (Accordingly)

By Manufacturing Type Analysis:

• In-house Manufacturing
• Contract Manufacturing Organizations

By Application Analysis:

• Oncology
• Blood Disorders
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications

By Product Analysis

• Recombinant Non-Glycosylated Proteins
o Insulin
o Recombinant Human Growth Hormones
o Granulocyte Colony-stimulating Factor
o Interferons
• Recombinant Glycosylated Proteins
o Erythropoietin
o Monoclonal Antibodies
o Follitropin
• Recombinant Peptides
o Glucagon
o Calcitonin

By Regional Analysis

North America
Europe
Asia-Pacific
Rest of the World

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Market to Cross US$ 11 Billion by 2021 here

News-ID: 580619 • Views:

More Releases from (MRE) Reports

Contrast Media Injectors Market share will Increase more than US$ 1.50 Billion By 2025
Contrast Media Injectors Market share will Increase more than US$ 1.50 Billion B …
In the past few years the demand for Contrast Media Injectors has increased. In contrast media injectors a radio opaque substance is injected in the body of human being for highlighting parts of the body for better diagnoses. Contrast Media Injectors enable radiologist to minutely analyze the normal and abnormal condition of human body. Research report clearly reflects that by 2025, there will be steady growth of more than US$
Healthcare Simulation Market is Expected to Cross US$ 2.50 Billion by 2022
The medical simulation market is segmented on the lines of its product and service, end user and geographic region. Based on product and service segmentation it covers simulation training services, simulation software, web based simulation, medical simulation anatomical models and endovascular simulators. Simulation software is further segmented into educational societies, custom consulting services and vender based training. Under simulation software it covers virtual tutors and performance recording software. Based on
Healthcare API Market is Expected to Exceed US$ 234 Million by 2024
The healthcare API market is segmented on the lines of its services, deployment model, and end user and on regional basis. Based on services segmentation it covers medical device (wearable), payment, remote patient monitoring, appointments and electronic health record access. Under deployment model segmentation it covers cloud based and on premise. End user segmentation covers vendors, patients, healthcare providers and healthcare payers. Browse Full Report @: https://www.marketresearchengine.com/reportdetails/healthcare-api-market-report How Big is the
Hazmat Suits Market is Expected to Exceed US$ 8.0 Billion by 2022
Hazmat Suits Market is Expected to Exceed US$ 8.0 Billion by 2022
The hazmat suits market is segmented on the lines of its application, end user, safety standards and regional. Based on application segmentation it covers hazardous materials, infection control and biohazard, chemical waste and others. Under end user segmentation the hazmat suits market covers healthcare, utilities, transportation, manufacturing, construction, mining and metallurgy, oil and gas and others. The hazmat suits market is segmented on the lines of its safety standards like

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.